Biblio
Export 2446 results:
Author Title Type [ Year] Filters: First Letter Of Keyword is A [Clear All Filters]
“Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Positive Modulator of HGF/MET, Fosgonimeton, in Healthy Volunteers and Subjects with Alzheimer's Disease: Randomized, Placebo-Controlled, Double-Blind, Phase I Clinical Trial.”, J Alzheimers Dis, vol. 86, no. 3, pp. 1399-1413, 2022.
, “Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Positive Modulator of HGF/MET, Fosgonimeton, in Healthy Volunteers and Subjects with Alzheimer's Disease: Randomized, Placebo-Controlled, Double-Blind, Phase I Clinical Trial.”, J Alzheimers Dis, vol. 86, no. 3, pp. 1399-1413, 2022.
, “Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Positive Modulator of HGF/MET, Fosgonimeton, in Healthy Volunteers and Subjects with Alzheimer's Disease: Randomized, Placebo-Controlled, Double-Blind, Phase I Clinical Trial.”, J Alzheimers Dis, vol. 86, no. 3, pp. 1399-1413, 2022.
, “Sex Differences in Behavior and Molecular Pathology in the 5XFAD Model.”, J Alzheimers Dis, vol. 85, no. 2, pp. 755-778, 2022.
, “Sex Differences in Behavior and Molecular Pathology in the 5XFAD Model.”, J Alzheimers Dis, vol. 85, no. 2, pp. 755-778, 2022.
, “Sex Differences in Behavior and Molecular Pathology in the 5XFAD Model.”, J Alzheimers Dis, vol. 85, no. 2, pp. 755-778, 2022.
, “Shortening of Saccades as a Possible Easy-to-Use Biomarker to Detect Risk of Alzheimer's Disease.”, J Alzheimers Dis, vol. 88, no. 2, pp. 609-618, 2022.
, “A Tale of Two Diseases: Exploring Mechanisms Linking Diabetes Mellitus with Alzheimer's Disease.”, J Alzheimers Dis, vol. 85, no. 2, pp. 485-501, 2022.
, “A Tale of Two Diseases: Exploring Mechanisms Linking Diabetes Mellitus with Alzheimer's Disease.”, J Alzheimers Dis, vol. 85, no. 2, pp. 485-501, 2022.
, “α-Lipoic Acid Has the Potential to Normalize Copper Metabolism, Which Is Dysregulated in Alzheimer's Disease.”, J Alzheimers Dis, vol. 85, no. 2, pp. 715-728, 2022.
, “α-Lipoic Acid Has the Potential to Normalize Copper Metabolism, Which Is Dysregulated in Alzheimer's Disease.”, J Alzheimers Dis, vol. 85, no. 2, pp. 715-728, 2022.
, “α-Lipoic Acid Has the Potential to Normalize Copper Metabolism, Which Is Dysregulated in Alzheimer's Disease.”, J Alzheimers Dis, vol. 85, no. 2, pp. 715-728, 2022.
, “α-Lipoic Acid Has the Potential to Normalize Copper Metabolism, Which Is Dysregulated in Alzheimer's Disease.”, J Alzheimers Dis, vol. 85, no. 2, pp. 715-728, 2022.
, “α-Lipoic Acid Has the Potential to Normalize Copper Metabolism, Which Is Dysregulated in Alzheimer's Disease.”, J Alzheimers Dis, vol. 85, no. 2, pp. 715-728, 2022.
, “α-Lipoic Acid Has the Potential to Normalize Copper Metabolism, Which Is Dysregulated in Alzheimer's Disease.”, J Alzheimers Dis, vol. 85, no. 2, pp. 715-728, 2022.
, “A 19-Year-Old Adolescent with Probable Alzheimer's Disease.”, J Alzheimers Dis, vol. 91, no. 3, pp. 915-922, 2023.
, “A 19-Year-Old Adolescent with Probable Alzheimer's Disease.”, J Alzheimers Dis, vol. 91, no. 3, pp. 915-922, 2023.
, “A 19-Year-Old Adolescent with Probable Alzheimer's Disease.”, J Alzheimers Dis, vol. 91, no. 3, pp. 915-922, 2023.
, “A 19-Year-Old Adolescent with Probable Alzheimer's Disease.”, J Alzheimers Dis, vol. 91, no. 3, pp. 915-922, 2023.
, “Activation of TNF Receptor 2 Improves Synaptic Plasticity and Enhances Amyloid-β Clearance in an Alzheimer's Disease Mouse Model with Humanized TNF Receptor 2.”, J Alzheimers Dis, vol. 94, no. 3, pp. 977-991, 2023.
, “Activation of TNF Receptor 2 Improves Synaptic Plasticity and Enhances Amyloid-β Clearance in an Alzheimer's Disease Mouse Model with Humanized TNF Receptor 2.”, J Alzheimers Dis, vol. 94, no. 3, pp. 977-991, 2023.
, “Activation of TNF Receptor 2 Improves Synaptic Plasticity and Enhances Amyloid-β Clearance in an Alzheimer's Disease Mouse Model with Humanized TNF Receptor 2.”, J Alzheimers Dis, vol. 94, no. 3, pp. 977-991, 2023.
, “Advanced Alzheimer's Disease Patients Show Safe, Significant, and Persistent Benefit in 6-Month Bryostatin Trial.”, J Alzheimers Dis, vol. 96, no. 2, pp. 759-766, 2023.
, “Age-Related Association Between APOE ɛ4 and Cognitive Progression in de novo Parkinson's Disease.”, J Alzheimers Dis, vol. 91, no. 3, pp. 1121-1132, 2023.
, “Age-Related Association Between APOE ɛ4 and Cognitive Progression in de novo Parkinson's Disease.”, J Alzheimers Dis, vol. 91, no. 3, pp. 1121-1132, 2023.
,